There have been significant advances in how we treat relapsed multiple myeloma within the past decade, which in turn has resulted in more effective treatments and an increase in survival rates. A very promising and novel approach is the application of chimeric antigen receptor (CAR) T cells, which have already demonstrated unprecedented clinical successes in the treatment of pediatric lymphoblastic leukemia. CAR-T cell therapy for myeloma targeting BCMA has shown high response rates, however, relapses remain. It has been found that myeloma cells lacking sufficient BCMA surface expression may be associated with relapse episodes, since these cells can escape immunity. A solution to prevent immune escape could be the simultaneous targeting of a second antigen.
In this SelectScience webinar, hear from experts Dr. Carlos Fernández de Larrea, Associate Professor of Medicine at the University of Barcelona, and Dr. Rogier M. Reijmers, Principle Scientist at LUMICKS, to find out how targeting BCMA and GPRC5D simultaneously with T cells engineered to express CARs specific for these antigens may prevent tumor cell escape, resulting in improved survival rates and short-term tumor reduction. Also discover how bicistronic edited CAR-T cells are showing higher interaction force with target cells using the LUMICKS’ z-Movi® Cell Avidity Analyzer, suggesting that this "multi-valent" approach is responsible for the enhanced activity in vivo.
Watch this webinar to learn:
Who should attend?
The live webinar takes place on Monday, October 19 at:
SelectScience runs 10+ webinars a month across various scientific topics, discover more of our upcoming webinars>>